Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8279989 | 0.90 | PROKR1 (0.74) | PROKR1PROKR2 | |
| SCHEMBL5434959 | 0.90 | PROKR1 (0.73) | PROKR1PROKR2 | |
| SCHEMBL8280035 | 0.90 | PROKR1 (0.73) | PROKR1PROKR2 | |
| SCHEMBL8280045 | 0.90 | PROKR1 (0.66) | PROKR1PROKR2 | |
| SCHEMBL5960121 | 0.89 | PROKR1 (0.73) | PROKR1PROKR2 | |
| SCHEMBL12530074 | 0.88 | PROKR1 (0.60) | PROKR1PROKR2 | |
| SCHEMBL5427240 | 0.87 | PROKR1 (0.61) | PROKR1PROKR2 | |
| SCHEMBL8280023 | 0.87 | PROKR1 (0.63) | PROKR1PROKR2 | |
| SCHEMBL325624 | 0.87 | PROKR1 (0.63) | PROKR1PROKR2 | |
| SCHEMBL10267954 | 0.86 | PROKR1 (0.75) | PROKR1PROKR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866290-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-01 | — | — | EP | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R (US) | 2012-09-27 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-8188081-B2 | Methods of treating inflammation using prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-05-29 | — | — | US | disclosed |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012006003-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| US-7968710-B2 | Gastrointestinal disorders;inflammatory bowel disorders; gastroesophageal reflux; constipation | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968710-B2 | Gastrointestinal disorders;inflammatory bowel disorders; gastroesophageal reflux; constipation | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20110136811-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R | 2011-06-09 | — | — | US | disclosed |
| US-20110136811-A1 | PROKINETICIN 1 RECEPTOR | MABUS JOHN R | 2011-06-09 | — | — | US | disclosed |
| US-7825117-B2 | Methods of modulating intestine epithelial functions | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-7825117-B2 | Methods of modulating intestine epithelial functions | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-02 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20070021422-A1 | Prokineticin 1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20070021422-A1 | Prokineticin 1 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | PROKR1 2/4885PROKR2 1/4885 |
| US-20110136811-A1 | PROKINETICIN 1 RECEPTOR | PROKR1, PROKR2, GIPR | PROKR1 1/4885PROKR2 2/4885 |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | PROKR1 1/4885PROKR2 2/4885 |
| US-20070021422-A1 | Prokineticin 1 receptor | PROKR1, PROKR2, GIPR | PROKR1 1/4885PROKR2 2/4885 |
| US-20120245077-A1 | PROKINETICIN 1 RECEPTOR | PROKR1, PROKR2, GIPR | PROKR1 1/4885PROKR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.